NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to analysts' expectations of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 brokerages have issued 12-month price targets for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they expect Aclaris Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 408.5% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

Media headlines about ACRS stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totalling 6,030,000 shares, an increase of 41.5% from the October 31st total of 4,260,000 shares. Based on an average trading volume of 1,940,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 18.8% of the company's stock are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include Cue Biopharma (CUE), Galera Therapeutics (GRTX), GlycoMimetics (GLYC), Albireo Pharma (ALBO), Seres Therapeutics (MCRB), Kalvista Pharmaceuticals (KALV), MannKind (MNKD), Neptune Wellness Solutions (NEPT), Minerva Neurosciences (NERV), Satsuma Pharmaceuticals (STSA), Calithera Biosciences (CALA), Xeris Pharmaceuticals (XERS), Syndax Pharmaceuticals (SNDX), Aeglea Bio Therapeutics (AGLE) and Spero Therapeutics (SPRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Exelixis (EXEL), Abeona Therapeutics (ABEO), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Tetraphase Pharmaceuticals (TTPH) and Viking Therapeutics (VKTX).

Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Man Group plc (9.02%), Endurant Capital Management LP (4.28%), State Street Corp (1.80%), Millennium Management LLC (0.63%), Virtu Financial LLC (0.13%) and Creative Planning (0.07%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Aclaris Therapeutics.

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Endurant Capital Management LP, State Street Corp, Millennium Management LLC and Creative Planning. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.77.

Aclaris Therapeutics has a market capitalization of $73.26 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]